Co-Diagnostics Announces Reverse Stock Split
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Co-Diagnostics (CODX) filed an amendment to implement a 1-for-25 reverse stock split effective November 24, 2026. The split takes effect at 12:01 a.m. ET, and split-adjusted trading begins at the Nasdaq Capital Market open that day.
The company intends the split to maintain compliance with Nasdaq’s $1.00 minimum bid price and preserve room to issue shares for equity financing as needed. Co-Diagnostics expects approximately 521,779 common shares outstanding after the split, compared with 13,044,465 currently. The number of authorized shares will not change.
Positive
- Minor point. Forward-looking: it has not happened yet and may not happen.Equity financing capacity is a stated aim of the split, which leaves the authorized share count unchanged
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.1-for-25 reverse stock split is intended to maintain compliance with Nasdaq’s $1.00 minimum bid price
News Explained
Outstanding options and warrants will cover fewer shares at higher exercise prices, while fractional-share entitlements round up.
The filed amendment remains pending until
A reverse stock split combines shares and proportionally raises the per-share price; the supplied definition says the split itself does not change company value.
Fractional-share entitlements will be rounded up to the next whole share rather than issued as fractions.
Details
Market Reaction – CODX
On Nov 19, the day this news came out, the latest delayed price for CODX is 5.95% below the previous close. Argus tracked a trough of -5.8% from its starting point during tracking. Our momentum scanner has recorded 24 alerts for this stock so far that day. The latest delayed price is $0.15. Relative volume is above average at 1.7x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Reverse split ratio
- 1-for-25
- Announced reverse stock split
- Effective time
- 12:01 a.m. ET on November 24, 2026
- Reverse stock split
- Minimum bid price requirement
- $1.00
- Nasdaq continued-listing requirement cited by the company
- Common shares outstanding
- 13,044,465 shares
- Before the reverse stock split
- Expected shares outstanding
- Approximately 521,779 shares
- Following the reverse stock split
Previous Stock split Reports
-
Announced a 1-for-30 reverse split; the stock's 24-hour price reaction was -21.16%.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
reverse stock split financial
cusip financial
par value financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
At the Special Meeting of Stockholders held on November 13, 2026 (the "Special Meeting"), the Company's stockholders approved an amendment to the Company's Articles of Incorporation, as amended, to effect one or more reverse stock splits of the Company's issued and outstanding shares of common stock, on one or more occasions, at a ratio of not less than 1-for-2, with the cumulative effect of all such reverse stock splits not to exceed 1-for-750, such final ratio or ratios and the timing and number of any reverse stock splits to be determined by the Company's board of directors at any time within twelve months following the Special Meeting, without further approval or authorization of the stockholders. Additional information regarding the Reverse Stock Split approved by stockholders can be found in the Company's definitive proxy statement filed with the Securities and Exchange Commission (the "SEC") on October 26, 2026.
The Amendment provides that at the effective time of the Reverse Stock Split, each 25 shares of the Company's issued and outstanding common stock will be automatically combined into one (1) validly issued, fully paid and non-assessable share of common stock, without effecting a change to the par value per share. The Reverse Stock Split will impact all shares of the Company's common stock outstanding immediately prior to the effective time of the Reverse Stock Split, as well as the number of shares of common stock available for issuance under the Company's equity incentive plans. In addition, the Reverse Stock Split will effect a reduction in the number of shares of common stock issuable upon the exercise of stock options and warrants outstanding immediately prior to the effectiveness of the Reverse Stock Split with a corresponding increase in the applicable exercise price per share, in each case in accordance with the terms thereof. The Reverse Stock Split will not change the number of shares of capital stock authorized for issuance under our Articles of Incorporation. Based on the 13,044,465 shares of common stock currently outstanding, we expect approximately 521,779 shares of common stock to be issued and outstanding following the Reverse Stock Split.
No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive fractional shares as a result of the Reverse Stock Split will have those shares rounded up to the next whole share. Stockholders with shares in brokerage accounts should direct any questions concerning the reverse stock split to their broker; all other stockholders may direct questions to the Company's transfer agent, VStock Transfer, LLC.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA") that are subject to a number of risks and uncertainties. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. There can be no assurance that implementing a reverse stock split will result in the Company maintaining compliance with Nasdaq listing requirements or that the Company will be able to conduct equity financings in the future. A discussion of additional risks and uncertainties can be found in the Company's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 31, 2026, and in the Company's other filings with the SEC, including Quarterly Reports on Form 10-Q. Co-Diagnostics undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-announces-reverse-stock-split-302946143.html
SOURCE Co-Diagnostics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.